An interventional study of Vercise Deep Brain Stimulation System in Parkinson Disease, sponsored by Boston Scientific Corporation. Completed at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Parkinson Disease by Boston Scientific Corporation — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Boston Scientific Corporation.
Among the 10 studies in Parkinson Disease by Boston Scientific Corporation, this one is the only one that started in 2017, is one of 6 with no phase, and was the 6th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →3 of the 10 studies in Parkinson Disease by Boston Scientific Corporation are open now, in 12 countries. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in Germany, United Kingdom
Boston Scientific Corporation · Sites in United States, Belgium, France and 3 more countries
Boston Scientific Corporation · Sites in United States, Argentina, Austria and 12 more countries
Ages 18+
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2017.
This study's enrollment of 69 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 53 across the 7 interventional studies, 1,500 across the 3 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 57 (88%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Parkinson Disease by Boston Scientific Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the performance of novel DBS programming methods compared to traditional programming methods.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Programming completed by a novel method first followed by Standard of care programming.
Device: Vercise Deep Brain Stimulation System
Programming completed as Standard of care followed by Novel programming.
Device: Vercise Deep Brain Stimulation System
Change in Motor Function
Mean change in Unified Parkinson's Disease Rating (UPDRS) Part III scores from Baseline meds off/stim off condition to Standard of care AND novel programming in meds off/stim on condition after randomization. Range 0 - 108. Higher scores indicate worse function.
Time frame: Programming visit Day 1 after Randomization
| Milestone | Standard of Care - Novel Algorithm Sequence | Novel Algorithm - Standard of Care Sequence |
|---|---|---|
| Started | 34 | 35 |
| Completed | 34 | 35 |
| Not completed | 0 | 0 |
Mean change in Unified Parkinson's Disease Rating (UPDRS) Part III scores from Baseline meds off/stim off condition to Standard of care AND novel programming in meds off/stim on condition after randomization. Range 0 - 108. Higher scores indicate worse function.
| Score on a scale | Standard of Care - Novel Algorithm Sequence | Novel Algorithm - SOC Sequence |
|---|---|---|
| Standard of Care vs Baseline Total UPDRS III Score Changes | 13.8 ± 10.7 | 16.5 ± 8.7 |
| Novel algorithm vs Baseline Total UPDRS III Score Changes | 15.7 ± 8.6 | 15.9 ± 7.8 |
Collected over Randomized subjects through the Programming visit Day 1. An average of 4-8 weeks for all subjects to complete study activities through the Programming visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care Programming | 0/69 (0%) | 0/69 (0%) | 2/69 (2.9%) |
| Novel Algorithm Programming | 0/69 (0%) | 0/69 (0%) | 0/69 (0%) |
| Event | Standard of Care Programming | Novel Algorithm Programming |
|---|---|---|
| Parkinson's DiseaseNervous system disorders | 2/69 | 0/69 |
Half of the participants were assigned to this arm.
| Age, Continuous(Years) | Standard of Care - Novel Algorithm Sequence | Novel Algorithm - Standard of Care Sequence | Total |
|---|---|---|---|
| Mean | 60.9 ± 6.5 | 60.9 ± 7.9 | 60.9 ± 7.2 |
| Sex: Female, Male(Participants) | Standard of Care - Novel Algorithm Sequence | Novel Algorithm - Standard of Care Sequence | Total |
|---|---|---|---|
| Female | 10 | 11 | 21 |
| Male | 24 | 24 | 48 |
| Race and Ethnicity Not Collected(Participants) | Standard of Care - Novel Algorithm Sequence | Novel Algorithm - Standard of Care Sequence | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Standard of Care - Novel Algorithm Sequence | Novel Algorithm - Standard of Care Sequence | Total |
|---|---|---|---|
| Germany | 34 | 35 | 69 |
| UPDRS-III score (meds off/stim off condition)(Units on a scale) | Standard of Care - Novel Algorithm Sequence | Novel Algorithm - Standard of Care Sequence | Total |
|---|---|---|---|
| Mean | 37.2 ± 13.1 | 35.7 ± 8.8 | 36.4 ± 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2017 to primary completion in Apr 2025, 98 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 98 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Scientific Corporation →